Invesco Ltd. Has $95.45 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Invesco Ltd. reduced its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 11.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,166,054 shares of the company’s stock after selling 146,042 shares during the quarter. Invesco Ltd.’s holdings in Vaxcyte were worth $95,453,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in Vaxcyte by 37.3% in the fourth quarter. Russell Investments Group Ltd. now owns 108,389 shares of the company’s stock worth $8,873,000 after buying an additional 29,442 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Vaxcyte by 12.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company’s stock worth $4,509,000 after acquiring an additional 6,121 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company’s stock valued at $5,916,000 after acquiring an additional 25,257 shares during the last quarter. Headlands Technologies LLC raised its stake in shares of Vaxcyte by 41.9% in the 4th quarter. Headlands Technologies LLC now owns 39,417 shares of the company’s stock valued at $3,227,000 after acquiring an additional 11,635 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Vaxcyte by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company’s stock valued at $229,495,000 after acquiring an additional 102,106 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Trading Up 11.3 %

Shares of NASDAQ:PCVX opened at $31.20 on Monday. The business’s 50 day moving average is $66.40 and its 200-day moving average is $85.55. The firm has a market capitalization of $4.02 billion, a PE ratio of -6.78 and a beta of 1.26. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insiders Place Their Bets

In other news, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,472,066.41. This trade represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,250 shares of company stock worth $3,170,738 over the last quarter. Company insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PCVX shares. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Evercore ISI upgraded shares of Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Bank of America cut their target price on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, The Goldman Sachs Group decreased their target price on Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and a consensus target price of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.